What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?
Spyre Therapeutics Inc SYRE
$85.69
βΌ -1.61%
($-1.40)
🎢 High Beta
Open
$88.10
Prev Close
$87.09
Day Range
$85.63 β $88.10
52W Range
$15.49 β $110.18
Market Cap
$7.56B
Beta
3.21
EPS (TTM)
$-2.32
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-04-07 |
| Shares Out. | 86,840,000 |
| Website | spyre.com/ β |
| Phone | 16176515940.0 |
| Employees | 112 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$36.2M |
| Free Cash Flow | -$208.9M |
| Total Assets | $1.17B |
| Total Liabilities | $71.9M |
| Equity | $1.10B |
About Spyre Therapeutics Inc
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting Ξ±4Ξ²7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Spyre Therapeutics Inc is a publicly traded company under the ticker symbol SYRE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
23 analysts (2026-09-01)